IFNAR
Interferon-α/β receptor; Interferon-alpha/beta receptor
The interferon-α/β receptor (IFNAR) is composed of two subunits, IFNAR1 and IFNAR2, encoding transmembrane polypeptides. Type-I IFNs, interferon α (IFN-α) and interferon β (IFN-β), act through a shared receptor complex, IFNAR. Binding of type-I IFN to IFNAR1 will robustly activate Janus activated kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway. Aberrant activation of the type-I IFN response results in a spectrum of disorders called interferonopathies.
Type-I IFN response occurs when IFN-α/β binds to their receptor complex, IFNAR. The ligand-receptor complex is phosphorylated, presumably by pre-associated Janus activated kinases (JAKs) namely tyrosine kinase 2 (TYK2) on IFNAR1 and JAK1 on IFNAR2. The phosphorylated receptors are docking sites for signal transducers and activators of transcription (STAT) factors that dimerise and translocate to the nucleus. STATs 1, 2, 3, 4, and 5 are activated by type-I IFNs in many cell types. Other kinases (e.g., mitogen-activated protein kinases) and transcription factors (e.g., nuclear factor-κB) can also be activated in response to type-I IFNs. Multiple pathways and IFN-regulated genes are activated by IFNs, many of which remain unknown.
All Product Categories
-
IFNAR Inhibitors
(120)
View all products
-
IFNAR Agonists
(11)
View all products
-
IFNAR Antagonists
(6)
View all products
-
IFNAR Activators
(84)
View all products
-
IFNAR Modulators
(4)
View all products
-
IFNAR Inducers
(23)
View all products
-
IFNAR Degrader
(1)
View all products
-
IFNAR Control
(1)
View all products
-
IFN-α/β Receptor Proteins
(16)
View all products
-
IFN-alpha/beta R2 Proteins
(6)
View all products
-
IFNAR Related Products (321)
Related Products (321)
-
Recombinant Proteins (16)
-
Antibodies (14)
-
TLC388
0 ImagesCat. No.: HY-19943CAS No.: 1432468-79-5TLC388 is a novel camptothecin analog with limited antitumor activity in metastatic NEC. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
ENDO12
0 ImagesCat. No.: HY-183079ENDO12 is an inhibitor of the Munc13-4-STX7 protein complex, with a Kd value of 2.7 µM for STX7. ENDO12 blocks the interaction of Munc13-4-STX7. ENDO12 inhibits endolysosomal flux, endolysosomal cargo degradation, the extracellular signal-regulated kinase signaling pathway in neutrophils, the IFN regulatory factor signaling pathway in plasmacytoid dendritic cells, and the responses of primary dendritic cells to TLR3, TLR7, and TLR9. ENDO12 alleviates CpG-induced systemic inflammation by reducing the levels of myeloperoxidase, IL-6 and IFNγ. ENDO12 does not interfere with the host's antiviral response to lymphocytic choriomeningitis virus infection.\nENDO12 can be used in studies related to systemic inflammation. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
STING Degrader-3
0 ImagesCat. No.: HY-168554STING Degrader-3 is a PROTAC-like STING degrader with a DC50 of 2.58 μM in THP-1 cells. STING Degrader-3 degrades STING protein via the lysosomal pathway. STING Degrader-3 functions as a non-degradative inhibitor in macrophages. STING Degrader-3 reduces the phosphorylation levels of TBK1 and IRF3, and downregulates the expression of IFN-β, CXCL10, IL-6, TNFα, IL-1β, ISG15 and ISG56. STING Degrader-3 exhibits renoprotective properties in a cisplatin-induced acute kidney injury model. STING Degrader-3 can be used in studies related to acute kidney injury. ((Pink: STING ligand (HY-168676); Blue: CRBN ligand (HY-126457); Black: linker (HY-W123015); CRBN ligand + linker: (HY-168677)). -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CLEC5A-IN-1
0 ImagesCat. No.: HY-184358CAS No.: 321941-76-8CLEC5A-IN-1 is an inhibitor that binds to CLEC5A, with a Kd value of 277 nM. CLEC5A-IN-1 inhibits HBV replication. CLEC5A-IN-1 induces the production of IFNα and IFNβ. CLEC5A-IN-1 reduces serum HBsAg and HBV DNA levels, as well as hepatic HBcAg levels, in HBV-infected animals. CLEC5A-IN-1 increases the positive rate and levels of serum HBsAb in HBV-infected animals. CLEC5A-IN-1 can be used for the research of hepatitis B. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
DF6002
0 ImagesCat. No.: HY-P991436Synonyms: BMS-986415 -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
NHWL071065
0 ImagesCat. No.: HY-182797CAS No.: 3117340-01-6NHWL071065 is a CRBN-targeting IKZF1/IKZF3 molecular glues degrader. NHWL071065 selectively degrades IKZF1 and IKZF3 in lymphoma cells via the ubiquitin-proteasome pathway. NHWL071065 inhibits the proliferation of lymphoma cells. NHWL071065 downregulates proteins involved in cytoskeleton assembly, cell adhesion and immune regulation in cells, while upregulating proteins related to the type I IFN signaling pathway. NHWL071065 can be used in the research of lymphoma. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
MyD88-IN-4
0 ImagesCat. No.: HY-178690CAS No.: 1801552-15-7MyD88-IN-4 is a MyD88 inhibitor. MyD88-IN-4 exerts antiviral effects by up-regulating IFN-β, and anti-inflammatory effects by inhibiting pro-inflammatory cytokine production. MyD88-IN-4 prevents MyD88 homodimer formation and its interaction with IRF3/IRF7. MyD88-IN-4 demonstrates efficacy against encephalitic alphavirus infections by reducing viral replication and improving survival in VEEV TC-83-infected mouse models. MyD88-IN-4 can be used for the study of alphavirus infections, bacterial toxin-related diseases, and sepsis. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
KZR-8445 TFA
0 ImagesCat. No.: HY-P10466AKZR-8445 TFA, a cyclic depsipeptide, is a client-selective Sec61 inhibitor. KZR-8445 TFA binds to the fully opened Sec61 lateral gate, blocks lumenal plug domain access, stabilizes lateral gate helices, traps select signal peptides, and disrupts secretory and membrane protein biogenesis. KZR-8445 TFA inhibits pro-inflammatory cytokine secretion in primary immune cells. KZR-8445 TFA inhibits SARS-CoV-2 replication, virus-induced cytotoxicity, and spike protein biogenesis. KZR-8445 TFA blocks disease progression in a mouse model of rheumatoid arthritis. KZR-8445 TFA can be used for the researches of rheumatoid arthritis and SARS-CoV-2 infection. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
KZR-8445
0 ImagesCat. No.: HY-P10466CAS No.: 2377734-91-1KZR-8445, a cyclic depsipeptide, is a client-selective Sec61 inhibitor. KZR-8445 binds to the fully opened Sec61 lateral gate, blocks lumenal plug domain access, stabilizes lateral gate helices, traps select signal peptides, and disrupts secretory and membrane protein biogenesis. KZR-8445 inhibits pro-inflammatory cytokine secretion in primary immune cells. KZR-8445 inhibits SARS-CoV-2 replication, virus-induced cytotoxicity, and spike protein biogenesis. KZR-8445 blocks disease progression in a mouse model of rheumatoid arthritis. KZR-8445 can be used for the researches of rheumatoid arthritis and SARS-CoV-2 infection. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Deucravacitinib-13C,d3
0 ImagesCat. No.: HY-166594SDeucravacitinib-13C,d3 is the 13C- and deuterium labeled Deucravacitinib. Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
ANB032
0 ImagesCat. No.: HY-P992182ANB032 is a human IgG4 kappa BTLA agonist monoclonal antibody. ANB032 inhibits activated T cell proliferation and reduces secretion of inflammatory cytokines. ANB032 can be used for the research of atopic dermatitis[1]. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Anti-Mouse IFNγRα/CD119 Antibody (2E2)
0 ImagesCat. No.: HY-P990232Anti-Mouse IFNγRα/CD119 Antibody (2E2) is an Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse IFNγRα/CD119. Anti-Mouse IFNγRα/CD119 Antibody (2E2) reacts with the mouse IFNγR (interferon gamma receptor) α chain also known as CD119 and IFNγ receptor 1. Anti-Mouse IFNγRα/CD119 Antibody (2E2) is a non-neutralizing antibody and does not block the binding of IFNγ to the receptor. Anti-Mouse IFNγRα/CD119 Antibody (2E2) can be used for detections of western blot, flow cytometry and immunoprecipitation. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- ITA-9
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CDN-3
0 ImagesCat. No.: HY-162844CAS No.: 2768839-23-0CDN-3 (Compound 10) is a cyclic dideoxy nucleotide derivative. CDN-3 can stimulate the production of IFN-β, activate the IRF-3 and NF-κB pathways, and induce the production of type I interferons as well as pro-inflammatory factors such as IL-6 and TNF-α. CDN-3 can inhibit cancer cells proliferation. CDN-3 can be used for research of colon cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Glycolipid C34
0 ImagesCat. No.: HY-186103CAS No.: 1204401-08-0Glycolipid C34, α-GalCer (HY-102022) analog, is a CD1d-binding glycolipid antinfection agent. Glycolipid C34 mediates invariant natural killer T cell activation and increases the secretion of IFN-γ and IL-4. Glycolipid C34 promotes clearance of bacterial infections in murine models and enhances protective immunity against viral infections. Glycolipid C34 can be used for the research of bacterial infection, viral infection. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Tyk2-IN-18-d3
0 ImagesCat. No.: HY-163314SCAS No.: 3018160-68-1 -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CD28-IN-3
0 ImagesCat. No.: HY-181507CAS No.: 850550-70-8CD28-IN-3 is a CD28 inhibitor with an IC50 of 7.80 μM and a Kd of 52.45 μM. CD28-IN-3 selectively blocks the CD28-B7 interaction, thereby inhibiting CD28-mediated costimulation. CD28-IN-3 suppresses the production of proinflammatory cytokines IFN-γ, IL-2 and TNF-α. CD28-IN-3 can be used in the research of checkpoint-resistant cancers. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Hycanthone (ethansulfonate)
0 ImagesCat. No.: HY-B1099BCAS No.: 64265-18-5Hycanthone ethansulfonate is an apurinic/apyrimidinic endonuclease 1 (APE1) inhibitor, DNA intercalator and Antischistosomal agent, with an IC50 of 80 nM against APE1. Hycanthone ethansulfonate irreversibly inhibits thymidine incorporation into DNA in adult sensitive *Schistosoma mansoni*, while exerts weak inhibitory effects on uridine and leucine incorporation. Hycanthone ethansulfonate reduces influenza virus-induced interferon production. Hycanthone ethansulfonate exhibits mutagenic effects in various organisms, shows teratogenicity in mice and rabbits, and induces neoplastic liver lesions in partially hepatectomized mice. Hycanthone ethansulfonate can be used in research related to schistosomiasis and cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Vadimezan (Standard)
0 ImagesSynonyms: DMXAA (Standard); ASA-404 (Standard)Vadimezan (Standard) (DMXAA (Standard)) is the analytical standard of Vadimezan (HY-10964). This product is intended for research and analytical applications. Vadimezan (DMXAA; ASA-404), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- IRF4 ligand-1
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
No matching results
No matching results
No matching results
No matching results
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results